Desmopressin vs Dihexa

Synthetic vasopressin analogue (V2R selective); crosses blood-brain barrier; enhances hippocampal LTP and memory consolidation; longer-acting than natural vasopressin

Desmopressin (DDAVP) is a synthetic analogue of arginine vasopressin (AVP) and an FDA-approved prescription medication indicated for central diabetes insipidus, primary nocturnal enuresis, and bleeding management in mild hemophilia A and von Willebrand disease type I. It exerts its primary therapeutic effects through V2 receptor activation in the renal collecting duct, increasing water reabsorption, and through DDAVP-mediated release of von Willebrand factor and factor VIII from endothelial storage sites. Research has also explored desmopressin effects on memory consolidation through vasopressinergic pathways in the brain, though controlled trials in healthy volunteers have produced inconsistent results, with some studies finding no measurable cognitive benefit. Desmopressin is available as nasal spray, sublingual tablet, and injectable formulations; use outside approved indications requires physician supervision, and hyponatremia is a documented and potentially serious risk, particularly in elderly patients. Desmopressin dosage and clinical contexts Desmopressin dosing varies by formulation and approved indication per FDA labeling. The nasal spray (DDAVP nasal spray, 100 mcg/mL) carries an FDA-indicated dose of 10–40 mcg once or twice daily for central diabetes insipidus; the intranasal formulation is no longer approved for primary nocturnal enuresis in adults due to hyponatremia risk. Oral and sublingual tablets include DDAVP for primary nocturnal enuresis (FDA label: 0.1–0.4 mg oral) and Nocdurna for nocturia in adults (FDA label: 27.7 mcg sublingual for women, 55.3 mcg sublingual for men, taken 1 hour before bed; FDA-approved 2018). Injectable desmopressin (4 mcg/mL) is indicated at 0.3 mcg/kg IV for perioperative hemostasis in hemophilia A and von Willebrand disease type I. The sublingual formulation for nocturia represents a significant expanded indication — nocturia affects a large proportion of older adults, and desmopressin's water-retention mechanism can reduce nightly urination frequency. Desmopressin vs vasopressin: Desmopressin is a structural modification of vasopressin — deamination of the N-terminal cysteine and substitution of D-arginine for L-arginine — that eliminates vasopressor (V1a receptor) activity while preserving antidiuretic (V2 receptor) potency, and dramatically extends the half-life from ~10 minutes to 1.5–3 hours. This selectivity makes desmopressin clinically safer than vasopressin for antidiuretic indications; vasopressin is reserved for contexts requiring vasopressor activity (septic shock, vasodilatory shock).

HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models

Dihexa is a synthetic small peptide drug candidate developed at Washington State University, proposed to augment cognitive function through potentiation of hepatocyte growth factor (HGF) and MET receptor signaling, a pathway that supports synaptic formation and hippocampal neuroplasticity. The underlying AT4/IRAP receptor system, through which dihexa is proposed to act, has been shown in preclinical rodent studies to enhance long-term potentiation (LTP) in hippocampal tissue and support neuroplastic processes associated with memory formation. Preclinical models have demonstrated memory-enhancing effects following dihexa administration; however, no peer-reviewed human clinical trials have been published as of 2025 and the compound does not appear in indexed biomedical literature under its common name. Dihexa is a research compound with no regulatory approval of any kind; it is not an approved pharmaceutical, and no human safety or pharmacokinetic data has been established. Dihexa administration in research contexts: the compound has been studied in rodent models via oral, intranasal, and subcutaneous routes, with preclinical data suggesting intranasal delivery may offer efficient CNS access due to olfactory pathway absorption. Nasal spray formulations are available through some research compound suppliers on this basis, though the clinical translatability of rodent CNS delivery data to humans has not been established. Dihexa is structurally derived from angiotensin IV and shares the AT4/IRAP receptor pharmacology of its precursor compounds; it is sometimes compared to semax and other nootropic peptides in terms of proposed cognitive mechanism, though its HGF/MET-dependent mechanism is distinct from the ACTH-fragment or NGF-upregulating mechanisms of semax and selank. The cognitive enhancement peptide landscape — and provider availability for researched compounds in this space — is covered in the PeptideBase cognitive peptides directory.